Danaher stock

DHR · NYSE · USD

$233.02Change from previous close: +0.37%Absolute change: +$0.86

Close · November 13, 2026

Price history

+5.34% over the period

1 year: from $221.20 (November 13, 2025) to $233.02 (November 13, 2026), +5.34%.

Show chart data

Closing prices adjusted for splits: the last close of each month.

DateClose
November 13, 2026$233.02
October 30, 2026$232.23
September 30, 2026$221.55
August 31, 2026$213.56
July 31, 2026$194.98
June 30, 2026$190.48
May 29, 2026$182.67
April 30, 2026$178.95
March 31, 2026$189.60
February 27, 2026$210.64
January 30, 2026$218.89
December 31, 2025$228.92
November 28, 2025$226.78
November 13, 2025$221.20

At a glance

  • The company

    Designs and manufactures professional, medical, research and industrial products and services for biotechnology, life sciences and diagnostics markets

  • Latest results

    Quarter to September 30, 2026 · EPS $2.11 (estimate $1.91)

TickerLandia's take on Danaher

Analysis calculated by TickerLandia from financial statements and prices, with public rules. Not investment advice. How we analyse stocks

Where the price stands

52-wk low$160.93
52-wk high$242.80

−4.03% from the 52-week high

Analysts · 24 analysts

Average target$259.90+11.54% vs. price

Buy 20 · Hold 4 · Sell 0 · Strong buy

TickerLandia Fingerprint: Danaher

Compared with similar companies: strong momentum.

Financials and price compared with 27 companies in the diagnostics & research industry, worldwide. Momentum and risk compared with 883 North American stocks.

Position in the group from 0 to 100 (100 = highest value): it describes, it does not rate. Tap a row for the metrics. Calculated on November 16, 2026. An indicator calculated by TickerLandia from financial statements and market data. How it is calculated

Valuation

Danaher is pricier than in the past and pricier than similar companies

On the latest fiscal year's earnings (2025), Danaher's P/E today is 46.1, above the median of its last 10 fiscal years (33.7; between 18.9 and 45.3 from 2016 to 2025). Danaher's P/E (trailing 12 months): 38.6, +6% against the median of a group of 10 similar companies (36.5).

P/E compared with its history

Compared with 10 similar companies

Danaher's metrics compared with similar companies
MetricDanaherPosition in the groupBand
P/E (trailing 12 months)38.6High
Forward P/E25.0Middle
Operating margin22.0%Middle
ROE8.2%Middle
Debt/equity0.52Low

P/E at fiscal year end; today on the latest fiscal year's earnings. Grey band: the middle half of the group; tick: the median; dot: Danaher. All multiples and dividends

TickerLandia analysisHow it is calculated

The financials

The business in numbers

Revenue

$6.55B

Latest quarter · Q3 2026

Net income

$1.24B

Latest quarter · Q3 2026

Quarterly net margin

18.8%

Latest quarter · Q3 2026

Numbers and valuation

Full valuation
Market cap
$163.94B
P/E
38.6
EPS
$6.04
Volume
3.34M
Daily trading
€865.44M
Dividend yield
0.65%
Last ex-dividend on September 30, 2026

How Danaher is changing

All results
  • Revenue grew 2.0% a year on average over the last 5 years

  • Operating margin fell from 28.3% to 19.1%

  • Profits turn into cash: free cash flow equal to 133% of net income

Returns

Danaher returns with dividends

$1,000 invested in Danaher 5 years ago, on November 15, 2021, would be worth $901 today with dividends reinvested: −9.95% in total, −2.08% per year. On price alone it would be $877 (−12.29%).

PeriodDanaherS&P 500$1,000 becomes
1 month+4.57%−3.12%$1,046
6 months+40.38%+1.58%$1,404
Year to date+1.79%+10.46%$1,018
1 year+6.13%+12.23%$1,061
3 years+21.02%+71.41%$1,210
5 years−9.95%+61.48%$901
10 years+250.02%+249.40%$3,500

Over the last 6 months it has done better than 78% of the stocks in the Healthcare sector.

From 1 year up with dividends reinvested, before taxes; under a year price only. S&P 500: price only. Calculate your investment

The chart in detail

Danaher: technical analysis

Danaher shows no clear trend: the price and its 50- and 200-session averages are not aligned. The price is 20.9% below its highest close since January 2, 1990 ($294.71, September 3, 2021).

Trend
No clear trend
RSI (14 sessions)
55
Between 30 and 70
vs 200-session average
+15.93%

Active signals

  • The price is moving in an unusually narrow range compared with the last year.

    since November 10, 2026

Support and resistance

Price areas where Danaher has stopped several times in the last year. They describe the chart; they are not forecasts.

  1. Resistance$238.30+2.26%2 touches, last on October 30, 2026
  2. Last price$233.02
  3. Support$232.59−0.19%2 touches, last on December 12, 2025
  4. Support$227.92−2.19%3 touches, last on September 28, 2026
  5. Support$222.79−4.39%2 touches, last on November 6, 2026

Volatility and risk

Over the last year it has moved less than the S&P 500.

Beta (1 year) vs S&P 500
0.56
Volatility (60 sessions, annualised)
27.5%
Largest fall in the last year
−33.11%

Close of November 13, 2026. Descriptive data calculated on daily prices: it describes the chart and is not investment advice. Beta and volatility describe the last year and can change a lot from one year to the next. How we calculate it

Danaher: seasonality

Average monthly price change over 37 years

+0.4%Jan+0.5%Feb+2.3%Mar+2.8%Apr+1.5%May+0.7%Jun+3.4%Jul−0.0%Aug−1.9%Sep+2.9%Oct+3.6%Nov+2.9%Dec

Over the last 37 years, the strongest month for Danaher has been November: +3.56% on average, positive in 27 years out of 36. The weakest has been September: −1.89% on average, positive in 15 years out of 37.

Show chart data
MonthAverageMedianPositive years
January+0.43%−0.30%16 of 36
February+0.51%+0.61%19 of 37
March+2.26%+1.69%24 of 37
April+2.81%+1.99%22 of 37
May+1.54%+1.66%24 of 37
June+0.69%+1.47%23 of 37
July+3.43%+3.48%26 of 37
August−0.03%+1.44%22 of 37
September−1.89%−0.76%15 of 37
October+2.91%+2.41%23 of 37
November+3.56%+3.28%27 of 36
December+2.94%+2.70%25 of 36

Price change only, dividends excluded. Past seasonality does not predict future moves.

The company

Danaher and its competitors

Hospitals, physicians' offices, reference laboratories and other critical care settings are among the customers for the company's clinical instruments, consumables, software and services, which are used to diagnose disease and support treatment decisions. Companies developing and manufacturing therapeutics buy its cell culture media, filtration technologies, chromatography resins, single-use hardware and manufacturing suite design services.

Headquarters
Washington, United States
Employees
58,000
Founded
1969
Chief executive
Julie Montgomery
Danaher and its competitors
CompanyMarket capOperating marginP/E (trailing 12 months)6 months
DanaherDHR$163.94B22.0%38.6+40.38%
Thermo Fisher ScientificTMO$259.44B19.1%36.9+56.99%
WatersWAT$90.45B16.0%192.6+37.42%
IDEXX LaboratoriesIDXX$55.48B32.5%47.0+33.21%
Agilent TechnologiesA$49.04B24.5%34.3+54.30%
NateraNTRA$46.27B-8.5%—+63.37%

Same industry or related industries, similar size. Compare Danaher with its competitors · Full profile